{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:04:30Z","timestamp":1772917470071,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Project of the Hungarian Society of Allergology and Clinical Immunology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Idiopathic inflammatory myopathies (IIMs), also known as myositis, are systemic autoimmune diseases characterized by chronic inflammation affecting the skin, muscles, and internal organs. Besides traditional risk factors and immune-mediated myocarditis, continuous activity of the immune system increases cardiovascular disease (CVD) risk, meaning that cardiovascular events are the leading causes of mortality in IIM patients. Statins are the most widely used lipid-lowering therapies, which reduce cardiovascular risk, but the fear of adverse muscular events inhibits the frequency of use. Methods: Our aim was to assess the CVD risk in a myositis cohort using the SCORE2 prediction system, carotid artery Doppler ultrasound measurement, and biomarkers; recommend individual lipid-lowering treatment; and follow the efficacy and adverse events of therapy in a 6-month treatment period. Results: The study population (80 IIM patients) was a middle-aged, female-dominant myositis cohort with an average disease duration of 9 years and low median global disease activity. Based on the SCORE2 evaluation, 78.8% of patients had medium\/high CVD risk, while 73.13% had asymptomatic carotid plaque. After 6 months of adequate lipid-lowering therapy, 37.5% of patients reached a lower CVD risk category, the biomarker levels of atherosclerosis significantly decreased, and no progression in carotid plaques was detected. None of the patients reported an adverse muscular event or IIM relapse. Conclusions: Our findings proved that the CVD risk of patients with myositis is high, but carefully applied lipid-lowering treatment is the key to effective risk reduction. Risk stratification and the recommendation of preventive treatment are the responsibility of the treating physician.<\/jats:p>","DOI":"10.3390\/jcm14103404","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T11:31:49Z","timestamp":1747135909000},"page":"3404","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of Efficacy and Safety of Lipid-Lowering Treatment and Its Importance in Risk Assessment and Prevention in a Hungarian Myositis Cohort"],"prefix":"10.3390","volume":"14","author":[{"given":"Dorottya","family":"Szinay","sequence":"first","affiliation":[{"name":"Division of Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Gyula Petr\u00e1nyi Doctoral School of Allergy and Clinical Immunology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-1703","authenticated-orcid":false,"given":"Katalin","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Division of Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Gyula Petr\u00e1nyi Doctoral School of Allergy and Clinical Immunology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Division of Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"B\u00e9ldi","sequence":"additional","affiliation":[{"name":"Division of Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Gyula Petr\u00e1nyi Doctoral School of Allergy and Clinical Immunology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Bencs","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Neuroscience, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5303-3082","authenticated-orcid":false,"given":"Hajnalka","family":"L\u0151rincz","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-9595","authenticated-orcid":false,"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Faculty of Health Sciences, Institute of Health Studies, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-7911","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Griger","sequence":"additional","affiliation":[{"name":"Division of Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Gyula Petr\u00e1nyi Doctoral School of Allergy and Clinical Immunology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Nagy-Vincze","sequence":"additional","affiliation":[{"name":"Division of Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Gyula Petr\u00e1nyi Doctoral School of Allergy and Clinical Immunology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/BOR.0000000000000442","article-title":"Cardiovascular involvement in myositis","volume":"29","author":"Diederichsen","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s10067-023-06599-4","article-title":"Cardiovascular manifestations in idiopathic inflammatory myopathies","volume":"42","author":"Shah","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1007\/s10067-019-04678-z","article-title":"Cardiac involvement in idiopathic inflammatory myopathies detected by cardiac magnetic resonance imaging","volume":"38","author":"Khoo","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/rheumatology\/kel311","article-title":"The heart in dermatomyositis and polymyositis","volume":"45","author":"Lundberg","year":"2006","journal-title":"Rheumatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13075-022-02906-7","article-title":"Subclinical systolic and diastolic myocardial dysfunction in polyphasic polymyositis\/dermatomyositis: A 2-year longitudinal study","volume":"24","author":"Balogh","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11926-020-00925-4","article-title":"Management of Myocarditis in Myositis: Diagnosis and Treatment","volume":"22","author":"Myhr","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1445-5994.2010.02406.x","article-title":"Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis","volume":"42","author":"Limaye","year":"2012","journal-title":"Intern. Med. J."},{"key":"ref_9","first-page":"1","article-title":"Cardiovascular disease as a leading cause of death: How are pharmacists getting involved?","volume":"8","author":"Alzubaidi","year":"2019","journal-title":"Integr. Pharm. Res. Pract."},{"key":"ref_10","first-page":"322","article-title":"Long-term survival of patients with idiopathic inflammatory myopathies: Anatomy of a single-centre cohort","volume":"41","author":"Yildirim","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/rheumatology\/kead271","article-title":"Cardiovascular risk in myositis patients compared with the general population","volume":"63","author":"Oreska","year":"2024","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10067-020-05237-7","article-title":"Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis","volume":"40","author":"Prieto","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-020-00942-3","article-title":"Lipid-lowering Therapies in Myositis","volume":"22","author":"Mizus","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar4135","article-title":"Atherosclerotic cardiovascular disease and dermatomyositis: An analysis of the Nationwide Inpatient Sample survey","volume":"15","author":"Linos","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/rheumatology\/kez076","article-title":"Increased risk of coronary heart disease among patients with idiopathic infammatory myositis: A nationwide population study in Taiwan","volume":"58","author":"Weng","year":"2019","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3899\/jrheum.181248","article-title":"Acute coronary syndrome in idiopathic infammatory myopathies: A population-based study","volume":"46","author":"Leclair","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_18","first-page":"461","article-title":"Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: A general population-based study","volume":"55","author":"Rai","year":"2016","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/03009742.2014.918652","article-title":"Increased subsequent risk of acute coronary syndrome for patients with dermatomyositis\/polymyositis: A nationwide population-based retrospective cohort study","volume":"44","author":"Lin","year":"2015","journal-title":"Scand. J. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/acr.22520","article-title":"Traditional cardiovascular risk factors and coronary artery calcifcation in adults with polymyositis and dermatomyositis: A danish multicenter study","volume":"67","author":"Diederichsen","year":"2015","journal-title":"Arthritis Care Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1093\/rheumatology\/keab851","article-title":"Cardiovascular events in adult polymyositis and dermatomyositis: A meta-analysis of observational studies","volume":"61","author":"Xiong","year":"2022","journal-title":"Rheumatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.semarthrit.2014.03.004","article-title":"Risk of coronary artery disease in patients with idiopathic infammatory myopathies: A systematic review and meta-analysis of observational studies","volume":"44","author":"Ungprasert","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: Results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.md.0000109755.65914.5e","article-title":"Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: A longitudinal study of 162 cases","volume":"83","author":"Ponyi","year":"2004","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/03009742.2019.1707281","article-title":"Incidence, survival, and risk of cardiovascular events in adult inflammatory myopathies in South Korea: A nationwide population-based study","volume":"49","author":"Jung","year":"2020","journal-title":"Scand. J. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e15337","DOI":"10.1111\/1756-185X.15337","article-title":"Statin-associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies","volume":"27","author":"Shah","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.medcli.2017.11.030","article-title":"Statins: Pros and cons","volume":"150","author":"Mammen","year":"2018","journal-title":"Med. Clin."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathogenic autoantibody internalization in myositis","volume":"83","author":"Pak","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/clc.23375","article-title":"Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: A retrospective study","volume":"43","author":"Bae","year":"2020","journal-title":"Clin. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11926-024-01143-y","article-title":"Decoding the Intricacies of Statin-Associated Muscle Symptoms","volume":"26","author":"Rastegar","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_31","first-page":"161","article-title":"Are statins anti-inflammatory?","volume":"1","author":"Blake","year":"2000","journal-title":"Curr. Control Trials Cardiovasc. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","unstructured":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration (2021). SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J., 42, 2439\u20132454."},{"key":"ref_34","unstructured":"(2023, March 01). Available online: https:\/\/www.escardio.org\/Education\/Practice-Tools\/CVD-prevention-toolbox\/HeartScore."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e030739","DOI":"10.1161\/JAHA.123.030739","article-title":"Carotid Plaque Score for Stroke and Cardiovascular Risk Prediction in a Middle-Aged Cohort from the General Population","volume":"12","author":"Vigen","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40256-023-00594-5","article-title":"Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention","volume":"23","author":"Michaeli","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sec-tional observational study of lipid-modifying therapy use in secondary and primary care: The DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non\u2013High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3174\/ajnr.A5078","article-title":"Lack of Association between Statin Use and Angiographic and Clinical Outcomes after Pipeline Embolization for Intracranial Aneurysms AJNR","volume":"38","author":"Brinjikji","year":"2017","journal-title":"Am. J. Neuroradiol."},{"key":"ref_43","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration (2024). Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: An individual participant data meta-analysis. Lancet Diabetes Endocrinol., 12, 306\u2013319."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S273","DOI":"10.1016\/j.hlc.2021.06.398","article-title":"The Use of PCSK9 Inhibitors in Treating Statin Induced Necrotising Myositis","volume":"30","author":"Soomro","year":"2021","journal-title":"Heart Lung Circ."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.12659\/MSM.893619","article-title":"Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?","volume":"21","author":"Zeman","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Poli, A., Marangoni, F., Corsini, A., Manzato, E., Marrocco, W., Martini, D., Medea, G., and Visioli, F. (2021). Phytosterols, Cholesterol Control, and Cardiovascular Disease. Nutrients, 13.","DOI":"10.3390\/nu13082810"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3404\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:06Z","timestamp":1760031126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14103404"],"URL":"https:\/\/doi.org\/10.3390\/jcm14103404","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}